Simpson 1976.

Methods	Allocation: randomised ‐ no further details. Blinding: double ‐ identical capsules. Duration: 4 weeks ‐ preceded by 3 day drug free period, evaluation carried out by the same physician, study lasted over 3 years. Setting: single centre.
Participants	Diagnosis: schizophrenia, acute (no further details). N=43. Age: mean 32 years, range 16‐61. Sex: 27 M, 16 F. Exclusion: ill health. History: newly hospitalised.
Interventions	1. Loxapine: dose mean 74 mg/day, range 30‐120 mg/day. N=24. 2. Trifluoperazine: dose mean 35 mg/day, range 20‐50 mg/day. N=19. Antiparkinsonian drugs and chlorayl hydrate as required.
Outcomes	Global effect (discharge). Leaving the study early. Adverse effects (Neurological Rating Scale, Unwanted Effects Checklist). Unable to use ‐ Global effect: CGI (no usable data). Mental state: BPRS (no usable data). Physiological measures: BP, ECG, ophthalmic tests, pulse (no data). Laboratory tests (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear